ADQUEY (difamilast 1%) FDA Approval: A Selective PDE4 Inhibitor for Atopic Dermatitis
On February 12, 2026, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for ADQUEY™ (difamilast 1%) ointment for the topical treatment of mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged 2 years and…